ReviewJournal of neuroendocrinology2026
The pituitary adenylate cyclase-activating polypeptide receptor and its splice variants: Unique roles in affective and motivated behavior.
Review in Journal of neuroendocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Pituitary adenylate cyclase-activating polypeptide (PACAP) is a pleiotropic neuropeptide with established roles in stress, affective behavior, and motivated behavior. Its primary receptor in the brain, the PACAP type I receptor (PAC1), has multiple variants due to alternative splicing of the gene, and these variants have been found to have different relationships with the stress response. In the field of motivated behavior, however, there has been much more limited research on these variants. This review focuses on the PAC1 and its splice variants, to propose that they should be thoroughly characterized in the context of motivated behavior. It develops the hypothesis that, for the motivated behavior of drug use, upregulation of a specific receptor variant during repeated episodes of drug use and withdrawal serves to reverse the early relationship between PACAP and drug use, switching from negative feedback in a non-dependent state to positive feedback in a dependent state. The review will first examine the known brain distribution and receptor dynamics of the PAC1 variants. Next, it will examine the known roles of PACAP and its receptor variants in stress, anxiety, and depression. Then, it will describe the known role of the PACAP system in alcohol use, as an example of drug use. Finally, the review will consider these known relationships in order to advance the proposal about how the PAC1 receptor variants may interact with drug use and dependence. Further research on this relationship could allow for the development of novel and effective medications for the treatment of drug use disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.